Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 69

1.

Markers of inflammation and their clinical significance.

Ballantyne CM, Nambi V.

Atheroscler Suppl. 2005 May;6(2):21-9. Review.

PMID:
15823493
2.
3.
4.

Statins and inflammatory markers.

Case CC, Ballantyne CM.

Curr Atheroscler Rep. 2002 Jan;4(1):42-7. Review.

PMID:
11772421
5.

Lp-PLA2: A new target for statin therapy.

Braun LT, Davidson MH.

Curr Atheroscler Rep. 2010 Jan;12(1):29-33. doi: 10.1007/s11883-009-0074-y. Review.

PMID:
20425268
6.

Inflammatory markers in coronary artery disease.

Ikonomidis I, Michalakeas CA, Parissis J, Paraskevaidis I, Ntai K, Papadakis I, Anastasiou-Nana M, Lekakis J.

Biofactors. 2012 Sep-Oct;38(5):320-8. doi: 10.1002/biof.1024. Epub 2012 May 24. Review.

PMID:
22628054
7.

High-sensitivity C-reactive protein and atherosclerotic disease: from improved risk prediction to risk-guided therapy.

Koenig W.

Int J Cardiol. 2013 Oct 15;168(6):5126-34. doi: 10.1016/j.ijcard.2013.07.113. Epub 2013 Aug 24. Review.

PMID:
23978367
8.

Inflammatory markers in coronary heart disease.

Madjid M, Willerson JT.

Br Med Bull. 2011;100:23-38. doi: 10.1093/bmb/ldr043. Epub 2011 Oct 18. Review.

PMID:
22010105
9.

[Inflammation and C-reactive protein in cardiovascular disease].

Munk PS, Larsen AI.

Tidsskr Nor Laegeforen. 2009 Jun 11;129(12):1221-4. doi: 10.4045/tidsskr.08.0011. Review. Norwegian.

10.

Review of the evidence for the clinical utility of lipoprotein-associated phospholipase A2 as a cardiovascular risk marker.

Corson MA, Jones PH, Davidson MH.

Am J Cardiol. 2008 Jun 16;101(12A):41F-50F. doi: 10.1016/j.amjcard.2008.04.018. Review.

PMID:
18549871
11.

Statins and other agents for vascular inflammation.

Owens CD.

J Vasc Surg. 2012 Dec;56(6):1799-806. doi: 10.1016/j.jvs.2012.08.045. Epub 2012 Sep 25. Review.

12.

Inflammation and the development of atherosclerosis.

Mizuno Y, Jacob RF, Mason RP.

J Atheroscler Thromb. 2011;18(5):351-8. Epub 2011 Mar 18. Review.

13.

High-sensitivity C-reactive protein and cardiovascular disease: a resolute belief or an elusive link?

Yousuf O, Mohanty BD, Martin SS, Joshi PH, Blaha MJ, Nasir K, Blumenthal RS, Budoff MJ.

J Am Coll Cardiol. 2013 Jul 30;62(5):397-408. doi: 10.1016/j.jacc.2013.05.016. Epub 2013 May 30. Review.

14.

[Does Lp-PLA2 determination help predict atherosclerosis and cardiocerebrovascular disease?].

Sertić J, Skorić B, Lovrić J, Bozina T, Reiner Z.

Acta Med Croatica. 2010 Oct;64(4):237-45. Review. Croatian.

PMID:
21688606
15.

Inflammatory biomarkers and statins.

Blanco-Colio LM, Tuñón J, Martín-Ventura JL, Egido J.

Drugs Today (Barc). 2005 Mar;41(3):171-7. Review.

PMID:
15883614
16.

Critical appraisal of inflammatory markers in cardiovascular risk stratification.

Krintus M, Kozinski M, Kubica J, Sypniewska G.

Crit Rev Clin Lab Sci. 2014 Oct;51(5):263-79. doi: 10.3109/10408363.2014.913549. Epub 2014 Jun 11. Review.

PMID:
24918900
17.

Lipoprotein-associated phospholipase A2: an independent predictor of coronary artery disease events in primary and secondary prevention.

Anderson JL.

Am J Cardiol. 2008 Jun 16;101(12A):23F-33F. doi: 10.1016/j.amjcard.2008.04.015. Review.

PMID:
18549868
18.

The role of lipoprotein-associated phospholipase A2 as a marker for atherosclerosis.

Virani SS, Nambi V.

Curr Atheroscler Rep. 2007 Aug;9(2):97-103. Review.

PMID:
17877917
19.

Biomarkers, C-reactive proteins and statins in acute coronary syndromes.

Ray KK.

Fundam Clin Pharmacol. 2007 Nov;21 Suppl 2:31-3. Review.

PMID:
18001319
20.

Emerging inflammatory markers for assessing coronary heart disease risk.

Corson MA.

Curr Cardiol Rep. 2009 Nov;11(6):452-9. Review.

PMID:
19863870

Supplemental Content

Support Center